Some studies have shown that IFN-γ is significantly increased in COVID-19 patients, and the antiviral activity of IFN-I, IFN-II, and IFN-III counterbalances ACE2 inducibility and restricts SARS-CoV-2 [38]. This evidence concerns the gene ACE2 and COVID-19.